Author

G. L. Beilhartz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Assay:protein structure· 1

Frequent Co-Authors

R. A. Melnyk· 3 shared A. W. Partridge· 1 shared B. A. Minassian· 1 shared B. Henry· 1 shared C. J. Brown· 1 shared C. W. Johannes· 1 shared D. P. Lane· 1 shared D. R. Gius· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCell Biology

R. A. Melnyk

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA)

S. Lim, R. Khoo, K. M. Peh, J. Teo, S. C. Chang, S. Ng, G. L. Beilhartz, R. A. Melnyk, C. W. Johannes, C. J. Brown, D. P. Lane, B. Henry, A. W. Partridge

This paper introduces bioPROTACs as intracellular biologics for targeted protein degradation, demonstrating their effectiveness against PCNA with rapid degradation and functional effects.

Proceedings of the National Academy of Sciences · Mar 2, 2020Peer-reviewedCell Biology

Exploiting toxin internalization receptors to enhance delivery of proteins to lysosomes for enzyme replacement therapy

S. Sugiman-Marangos, G. L. Beilhartz, X. Zhao, D. Zhou, R. Hua, P. K. Kim, J. M. Rini, B. A. Minassian, R. A. Melnyk

This study creates a chimera of diphtheria toxin and TPP1 to enhance lysosomal enzyme delivery, showing improved uptake and efficacy in a mouse model.

bioRxiv · Jan 22, 2020Pharmacology & Toxicology

Inhibition of tumor growth by a novel engineered chimeric toxin that cleaves activated mutant and wild-type RAS

V. Vidimar, G. L. Beilhartz, M. Park, M. Biancucci, M. B. Kieffer, D. R. Gius, R. A. Melnyk, K. J. Satchell

This paper develops a chimeric toxin that cleaves both mutant and wild-type RAS, reducing tumor burden in mouse models.

bioRxiv · Dec 17, 2019Cancer Biology